Catheter-Associated Urinary Tract Infections Treatment Market Forecast To Reach $1.67 Billion By 2030: Key Trends Explained
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Catheter-Associated Urinary Tract Infections Treatment Market CAGR Outlook And Future Development
The catheter-associated urinary tract infections treatment market has experienced robust expansion in recent years. It is projected to grow from $1.26 billion in 2025 to $1.33 billion in 2026, at a compound annual growth rate (CAGR) of 5.7%. This historical growth can be attributed to the increasing prevalence of catheter-associated urinary tract infections, a rise in patient volumes within hospitals and clinics, the adoption of antibiotics for treatment, the development of healthcare infrastructure, and heightened awareness of infection control measures.
The catheter-associated urinary tract infections treatment market is poised for significant expansion over the coming years. Its valuation is projected to reach $1.67 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.9%. This anticipated growth during the forecast period is primarily driven by factors such as the increasing embrace of urinary catheter coatings, the rising application of probiotics and immunotherapy, a heightened need for personalized treatment options, the expansion of online drug delivery and telehealth services, and a greater emphasis on preventive care and early intervention. Key developments expected in this period encompass the growing preference for non-antibiotic therapies, an escalating demand for catheter coatings and antimicrobial devices, a reinforced focus on customized CAUTI treatment approaches, the broadening of online and retail drug distribution channels, and enhanced public awareness regarding the early detection and prevention of CAUTI.
Get A Free Sample Report With In-Depth Market Insights:
Catheter-Associated Urinary Tract Infections Treatment Market Expansion Drivers: What’s Shaping Future Growth?
Future growth in the catheter-associated urinary tract infections treatment market is anticipated to be fueled by an increase in hospital-acquired infection rates. These rates signify how often patients acquire infections while hospitalized, which were not present upon their admission. The main cause of this increase is antimicrobial resistance, enabling pathogens to withstand typical treatments and spread readily within medical environments. Catheter-associated urinary tract infections treatment contributes to decreasing hospital-acquired infections by efficiently preventing and managing those linked to indwelling catheters, consequently boosting patient safety and diminishing healthcare-associated complications. As an illustration, the Center for Infectious Disease Research and Policy (CIDRAP), a US-based disease research organization, reported in May 2024 that approximately 4.3 million patients annually in hospitals throughout the European Union and European Economic Area contracted at least one healthcare-acquired infection during 2022 and 2023. Thus, the escalation in hospital-acquired infection rates is a key factor propelling the expansion of the catheter-associated urinary tract infections treatment market.
Catheter-Associated Urinary Tract Infections Treatment Market Segment Landscape: Which Areas Lead Development?
The catheter-associated urinary tract infections treatment market covered in this report is segmented –
1) By Treatment Type: Antibiotics, Non-Antibiotic Therapies
2) By Drug Type: Penicillin And Combinations, Quinolones, Cephalosporin, Aminoglycoside Antibiotics, Sulphonamides, Azoles And Amphotericin B, Tetracycline, Nitrofurans, Other Drug Types
3) By Indication Type: Asymptomatic Catheter-Associated Urinary Tract Infection, Symptomatic Catheter-Associated Urinary Tract Infection
4) By Distribution Channel: Hospital Pharmacies, Gynaecology And Urology Clinics, Drug Stores, Retail Pharmacies, Online Drug Stores
5) By End-Users: Clinic, Hospital, Other End-Users
Subsegments:
1) By Antibiotics: Penicillins, Cephalosporins, Fluoroquinolones, Aminoglycosides, Sulfonamides
2) By Non-Antibiotic Therapies: Urinary Catheter Coatings, Probiotics, Cranberry Extracts, Immunotherapy, Bladder Irrigation Solutions
Catheter-Associated Urinary Tract Infections Treatment Market Strategic Trends: What Defines The Next Growth Phase?
Companies operating within the catheter-associated urinary tract infection treatment market are increasingly focusing on the development of advanced solutions, such as automated bladder irrigation systems, to enhance infection prevention and standardize catheter care practices. These automated systems represent a technology designed to control the inflow and outflow of irrigation fluid via sensors, thereby delivering safe and consistent cleansing cycles while minimizing contamination risks through a closed-system design. As an illustration, in January 2026, UMED Inc., a healthcare company from South Korea, globally unveiled UroRinse Light at CES 2026. This product was introduced as the world’s first fully automated and standardized bladder irrigation system specifically engineered for individuals using long-term urinary catheters. The system employs sensor-based automated control to manage irrigation flow, ensuring reproducible treatment cycles and significantly reducing contamination thanks to its closed structure. It supports usage across various environments, including hospitals, care facilities, and home settings, thus enabling patients and their caregivers to perform safe and repeatable bladder irrigation procedures beyond conventional clinical environments. Furthermore, the device integrates with a mobile application and a cloud database to record irrigation history and track patient status, with future plans for integration into EMR systems and remote care platforms to bolster continuous monitoring and proactive infection prevention efforts.
Catheter-Associated Urinary Tract Infections Treatment Market Leading Players And Competitive Positioning
Major companies operating in the catheter-associated urinary tract infections treatment market are Cardinal Health Inc., Pfizer Incorporated, Bayer Aktiengesellschaft, AstraZeneca Public Limited Company, Medline Industries, Limited Partnership, Becton, Dickinson Company, B. Braun Societät mit beschränkter Haftung, Merck Company Inc, Coloplast A/S, Teleflex Incorporated, ConvaTec Group Public Limited Company, Hollister Incorporated, Vygon S.A., Wellspect Healthcare AB, Urocare Products Inc, Paul Hartmann Aktiengesellschaft, Bactiguard AB, NanoVibronix Inc, WellLead Medical Co Limited, Poiesis Medical LLC.
View The Full Catheter-Associated Urinary Tract Infections Treatment Market Report:
Catheter-Associated Urinary Tract Infections Treatment Market Regional Distribution: Which Areas Power Market Growth?
North America was the largest region in the catheter-associated urinary tract infections treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the catheter-associated urinary tract infections treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
